Product Information
CANASA 1,000 MG SUPPOSITORY is a brand product labeled by Allergan, Inc., priced at $37.1097 per EA under NDC 58914050156. Its NADAC has been published 519 times since Nov 28, 2013.
FDA first approved this application on Jan 5, 2001. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the Mesalamine market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
1000 mg/1
Manufacturer
Allergan, Inc.NDC
58914050156
Classification
Brand
Dosage Form
SUPPOSITORY
Route
RECTAL
Effective Date
9/23/2026
Active Ingredients
MESALAMINEApproval Type
New Drug (NDA)
FDA Application
NDA021252FDA Approved
1/5/2001
TE Code
AB
On Market Since
1/5/2001
Pharmacological Classes
Price Statistics
The NADAC for CANASA 1,000 MG SUPPOSITORY has been published 519 times since Nov 28, 2013, and over the history we have for it it has risen 79.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $37.1097 per EA |
|---|---|
| All-time high | $37.3266 (Jul 16, 2025) |
| All-time low | $20.6321 (Nov 28, 2013) |
| 52-week high | $37.3091 |
| 52-week low | $37.0647 |
| Median price | $33.9526 |
| Average price | $32.3189 |
| Largest weekly change | +15.0% (Jul 8, 2015) |
| Weeks tracked | 519 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 7 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 97% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Allergan, Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mesalamine market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aminosalicylate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CANASA 1,000 MG SUPPOSITORY?
The current National Average Drug Acquisition Cost (NADAC) for CANASA 1,000 MG SUPPOSITORY, manufactured by Allergan, Inc., is $37.1097 per EA (NDC 58914050156), effective Sep 30, 2026.
How has the price of CANASA 1,000 MG SUPPOSITORY changed over time?
Over the history we have for it, the NADAC for CANASA 1,000 MG SUPPOSITORY has risen 79.9%. It has been tracked across 519 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for CANASA 1,000 MG SUPPOSITORY?
Since Nov 28, 2013, the NADAC for CANASA 1,000 MG SUPPOSITORY has ranged from a low of $20.6321 (Nov 28, 2013) to a high of $37.3266 (Jul 16, 2025), with a median of $33.9526 per EA.
Are there cheaper alternatives to CANASA 1,000 MG SUPPOSITORY?
Yes. 7 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, MESALAMINE 1,000 MG SUPP, is $1.2838 per EA — about 97% below CANASA 1,000 MG SUPPOSITORY.
Who manufactures CANASA 1,000 MG SUPPOSITORY?
CANASA 1,000 MG SUPPOSITORY (NDC 58914050156) is labeled by Allergan, Inc., and CMS classifies it as a brand product.